Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $1.14, down 2.57% on the session, giving a market capitalisation of $776,975. On trailing twelve-month figures it carries a trailing P/E of -0.26, a net margin of 0.0%. Its beta of 0.69 implies it has historically moved less than the broad market.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Dermata Therapeutics, Inc. is most often compared with the following Healthcare names: